PPV-06 / Peptinov - LARVOL DELTA

Safety and immunogenicity of PPV-06, an active anti-IL-6 immunotherapy targeting low-grade inflammation against knee osteoarthritis: a randomized, double-blind, placebo-controlled, clinical phase 1 study. (PubMed, Nat Commun) - P1 | "All participants receiving PPV-06 exhibit anti-IL-6 antibodies, and interestingly, participants with higher IL-6 neutralizing capacity exhibit an improved clinical outcome, as determined by changes in KOOS scores. These findings support further development of PPV-06 as a promising therapeutic strategy for knee osteoarthritis."

Clinical • Journal • P1 data • Dermatology • Immunology • Inflammation • Osteoarthritis • Pain • Pruritus • Rheumatology

PPV-06 Vaccine in Inflammatory Knee Osteoarthritis (clinicaltrials.gov) - P2 | N=204 | Not yet recruiting | Sponsor: Peptinov SAS | Trial completion date: Dec 2027 ➔ Dec 2028 | Trial primary completion date: Dec 2027 ➔ Dec 2028

Trial completion date • Trial primary completion date • Immunology • Osteoarthritis • Pain • Rheumatology

Safety and Immunogenicity of an Active Anti-IL-6 Immunotherapy in a Phase 1 Clinical Trial in Knee Osteoarthritis Patients (ACR Convergence 2024) - P1 | "The PPV-06 active immunotherapy administered to patients with inflammatory KOA at two dose levels (10 µg and 50 µg) demonstrated a favorable safety profile and the evidence of immunogenicity in both PPV-06 treated groups. This outcome represents a significant milestone in the development of the PPV-06 active immunotherapy program."

Clinical • IO biomarker • P1 data • Immunology • Infectious Disease • Inflammation • Osteoarthritis • Pain • Rheumatology • CRP

PPV-06 Vaccine in Inflammatory Knee Osteoarthritis (clinicaltrials.gov) - P2 | N=204 | Not yet recruiting | Sponsor: Peptinov SAS

New P2 trial • Immunology • Osteoarthritis • Pain • Rheumatology • CRP • IL6

SAFETY AND IMMUNOGENICITY OF AN ACTIVE ANTI-IL-6 IMMUNOTHERAPY IN A PHASE 1 CLINICAL TRIAL IN KNEE OSTEOARTHRITIS PATIENTS (EULAR 2024) - P1 | "The PPV-06 active immunotherapy administered to patients with inflammatory KOA at two dose levels (10 µg and 50 µg) demonstrated a favorable safety profile and the evidence of immunogenicity in both PPV-06 treated groups. This outcome represents a significant milestone in the development of the PPV-06 active immunotherapy for the treatment of patients with inflammatory KOA."

Clinical • IO biomarker • Late-breaking abstract • P1 data • Back Pain • Dermatology • Dysphonia • Immunology • Infectious Disease • Musculoskeletal Pain • Osteoarthritis • Pain • Pruritus • Rheumatology • CRP

Dose Escalation Study Assessing the Safety and Immune Response of PPV-06 Vaccine (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Peptinov SAS | Recruiting ➔ Completed

Trial completion • Immunology • Osteoarthritis • Pain • Rheumatology

Dose Escalation Study Assessing the Safety and Immune Response of PPV-06 Vaccine (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Peptinov SAS | Trial completion date: Apr 2022 ➔ Feb 2023 | Trial primary completion date: Apr 2022 ➔ Feb 2023

Trial completion date • Trial primary completion date • Immunology • Osteoarthritis • Pain • Rheumatology • CD4 • CRP • IFNG • IL17A • IL5

Dose Escalation Study Assessing the Safety and Immune Response of PPV-06 Vaccine (clinicaltrials.gov) - P1; N=24; Recruiting; Sponsor: Peptinov SAS; Not yet recruiting ➔ Recruiting; Trial completion date: Oct 2021 ➔ Apr 2022; Initiation date: Sep 2020 ➔ Feb 2021; Trial primary completion date: Oct 2021 ➔ Apr 2022

Clinical • Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Immunology • Osteoarthritis • Pain • Rheumatology • CD4 • IFNG • IL17A • IL5

Dose Escalation Study Assessing the Safety and Immune Response of PPV-06 Vaccine (clinicaltrials.gov) - P1; N=24; Not yet recruiting; Sponsor: Peptinov SAS

Clinical • New P1 trial • Immunology • Osteoarthritis • Pain • Rheumatology